Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Kisqali, breast cancer
Black Patients With Triple-Negative Breast Cancer Miss Immunotherapy
In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates than white
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer
Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), reported Peter Schmid, MD, PhD, of Barts Cancer Institute and Queen Mary University in London, at the European Society for Medical Oncology congress in Barcelona.
Subtype-Dependent Health Disparities Among Breast Cancer Patients
Breast cancer remains the most common invasive cancer diagnosed in women in the United States, accounting for about one in three new female cancers each ye | Cancer
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence,
1d
Black patients with triple-negative breast cancer may be less likely to receive immunotherapy than white patients
In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...
Newser on MSN
5h
Big Disparity Exists on Black Women, Breast Cancer
A new meta-study shows that Black women are 40% more likely than white women to die from all types of breast cancer, and ...
3d
on MSN
Black women are more likely than white women to die of all types of breast cancer
Black women are more likely than white women to die from even the most treatable types of breast cancer, a study published ...
3d
Triple Negative Breast Cancer Clinical Trials, Treatment Drugs, Pipeline Insights, and Companies 2024
Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...
2d
on MSN
When Toks Olagundoye Got Breast Cancer, Her ‘Frasier’ Co-Stars Stepped Up
My work makes me really happy,” says Toks Olagundoye, an acting veteran who plays Olivia Finch on the Paramount+ reboot of ...
Science Daily
6d
Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer
Researchers have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings show two distinct patterns of B cell ...
EurekAlert!
13d
Double trouble for triple-negative breast cancer
Hollings Cancer Center researchers have identified one reason why triple-negative breast cancer becomes resistant to ...
News Medical
11d
PDX engraftment predicts high recurrence and poor survival in triple-negative breast cancer
Researchers examine the association between patient-derived xenograft with recurrence and survival rates in triple negative ...
6d
I didn’t have sex for a year after breast cancer – no one talks about this
Breast cancer runs in my family so I’ve always been vigilant about self-checking. As soon as I found a lump, in 2021, I went ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback